The result from first patient dosed with VMT-α-NET in India on a compassionate use basis showed favorable responses. The initial response was measured by a somatostatin imaging agent 68Ga-DOTANOC and demonstrated surprisingly favorable results after a single low dose...
Fiscal Calendar Year Changes from June to December Year End RICHLAND, WASHINGTON & CORALVILLE, IOWA – February 16, 2023 Perspective, Therapeutics Inc. (formerly known as Isoray, Inc.) (NYSE AMERICAN: ISR), a precision oncology company developing alpha-particle...
Company’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and website introduced New ticker symbol to be NYSE American: CATX RICHLAND, WASHINGTON & CORALVILLE, IOWA – February...
The combination delivers the promise of bringing powerful new perspectives to the rapidly emerging field of Alpha-Particle radiopharmaceuticals RICHLAND, WASHINGTON & CORALVILLE, IOWA – February 6, 2023 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company...
Stockholders Approve Proposal One Clearing Way for Consummation of Merger RICHLAND, WASHINGTON – January 30, 2023 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the...
RICHLAND, WASHINGTON – January 12, 2023 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the January 12th, 2023, adjourned Annual...
By CEO Lori Woods We began this journey with a simple truth. Standing still is never an option. And the history of Isoray underscores that reality. When Isoray was founded, we were focused on the treatment of prostate cancer utilizing Cesium-131. Some saw it as a...
RICHLAND, WASHINGTON – December 14, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the December 13th, 2022, Annual Meeting is...
By Peter T. Heiberger, M.S. DABR, RSOLead Medical Physicist, Radiation Oncology, Aurora Health Care, Green Bay, WI When I think about Cesium-131 an old expression comes to mind. “It's the little details that are vital. Little things make big things happen.” When it...
Revenue Increased 12% Year-Over-Year Record Non-Prostate Brachytherapy Revenue Increased 28% Year-Over-Year RICHLAND, WASHINGTON – November 10, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering...
Conference Call is Thursday, November 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – October 31, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...